Biocept Reports Second Quarter 2018 Financial Results
(WorldNews Health)

SAN DIEGO, Aug. 14, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and six months ended June 30, 2018, and provides an update on its business progress. `We strengthened our financial position by completing a shareholder rights offering yesterday which added over $10 million to the balance sheet and by retiring our long-term debt in July, which reduces annual cash expenditures by more than $2 million,` said Michael Nall, President and CEO of Biocept. `We have also undergone refinements...